genetic mutation ka mālama ʻana i ka maʻi kanesa

Ka hoomaopopo ana i ke kuleana o genetic mutation ka mālama ʻana i ka maʻi kanesa He mea koʻikoʻi ia no ka mālama ʻana i ka maʻi maʻi maʻi maʻi pilikino a maikaʻi. ʻIke ʻia kēia ʻatikala pehea e hōʻike ai ka hoʻāʻo genetic i nā hoʻoholo lapaʻau, nā ʻano hoʻololi i loaʻa maʻamau i ka maʻi kanesa āpau, a me nā lāʻau lapaʻau i kuhikuhi ʻia i kēia mau hoʻololi kikoʻī. Understanding Genetic Mutations in Lung Cancer genetic mutation ka mālama ʻana i ka maʻi kanesa. Hiki i kēia mau hoʻololi ke loaʻa i nā genes e hoʻomalu i ka ulu ʻana o ka cell, ka mahele, a me ka hoʻoponopono. He mea nui ka ʻike ʻana i kēia mau hoʻololi ʻana no ka mea hiki ke alakaʻi i nā hoʻolālā lapaʻau a hoʻomaikaʻi i nā hopena maʻi. Ma Shandong Baofa Cancer Research Institute, hoʻomaka mua mākou i ka hoʻomaopopo ʻana i ka ʻāina genetic o kēlā me kēia maʻi maʻi maʻi kanesa. He aha nā Genetic Mutations?ʻO ka mālama ʻana i ka maʻi kanesa maʻi maʻi genetic mutation he mau hoʻololi i ke kaʻina DNA e hiki ai ke alakaʻi i ke ʻano o ka cell cell abnormal. Hiki ke hoʻoilina a loaʻa paha kēia mau hoʻololi ʻana i ke ola o ke kanaka. I ka ma'i 'a'ai ma'i 'a'ai, 'oi aku ka ma'amau o ka ho'ololi 'ana a ke kumu pinepine 'ia e nā kumu kaiapuni e like me ka puhi paka a i 'ole ka 'ike 'ana i nā mea haumia. Hiki i kēia mau hoʻololi ke hoʻopau i nā kaʻina kelepona maʻamau, e alakaʻi ana i ka ulu ʻana ʻole a me ka hoʻokumu ʻana o nā maʻi ʻaʻai. He mea nui ka hoʻomaopopo ʻana i kēia mau mutation no ke koho ʻana i ke ala lapaʻau kūpono. Eia kekahi mau mea maʻamau:EGFR (Epidermal Growth Factor Receptor): He mea maʻamau ka hoʻololi ʻana i ka EGFR i ka maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi (NSCLC), ʻoi aku ka nui o nā adenocarcinomas. Hiki i kēia mau hoʻololi ʻana ke hoʻololi i nā maʻi kanesa i ʻoi aku ka naʻau o kekahi mau lāʻau lapaʻau.ALK (Anaplastic Lymphoma Kinase): ʻO ka hoʻololi hou ʻana o ALK kekahi ʻano hoʻololi i ʻike ʻia ma NSCLC. Ua hōʻike ka poʻe ALK inhibitors i ka kūleʻa nui i ka mālama ʻana i nā ʻōpū me kēia mutation.ROS1: E like me ALK, hiki i ka hui ʻana o ROS1 ke hoʻoulu i ka ulu ʻana o ka maʻi kanesa. Loaʻa ka ROS1 inhibitors no nā poʻe maʻi me ka ROS1-positive NSCLC.BRAF: Hiki ke loaʻa nā hoʻololi BRAF, ʻoi aku ka hoʻololi ʻana o V600E, ma NSCLC. Hiki ke hoʻohana ʻia ka BRAF inhibitors e hoʻopaʻa i kēia mau hoʻololi.KRAS: He mea maʻamau ka hoʻololi ʻana o KRAS i ka adenocarcinoma māmā. ʻOiai paʻakikī ka mōʻaukala, ke kū nei nā lāʻau lapaʻau hou e mālama i nā maʻi maʻi maʻi KRAS-mutated.PD-L1 (Palapala ʻia Make-Ligand 1): ʻOiai ʻaʻole ia he mutation gene i ke ʻano kuʻuna, ʻo ka ʻōlelo PD-L1 kahi biomarker hiki ke wānana i ka pane ʻana i ka immunotherapy. Hōʻike paha ka ʻōlelo PD-L1 kiʻekiʻe e ʻoi aku ka maikaʻi o ka mea maʻi mai ka immunotherapy. Genetic Testing for Lung CancerʻO ka mālama ʻana i ka maʻi kanesa maʻi maʻi genetic mutation ʻike ʻia ma o ka hoʻāʻo genetic piha, ʻike ʻia ʻo ia ka hoʻāʻo biomarker a i ʻole ka molecular profiling. Hoʻopili kēia hoʻāʻo ʻana i ka ʻiʻo tumora a i ʻole, i kekahi mau hihia, nā laʻana koko e ʻike ai i nā hoʻololi genetic kikoʻī e alakaʻi nei i ka ulu ʻana o ke kanesa. ʻO nā hopena o kēia mau hoʻāʻo e kōkua i ka poʻe oncologists e hoʻopilikino i nā hoʻolālā lapaʻau e kuhikuhi i nā ʻano kūʻokoʻa o kēlā me kēia maʻi maʻi maʻi. Ke hoʻohana nei ʻo Baofa Cancer Research Institute i nā ʻenehana hoʻāʻo genetic hou.Ke Kaʻina Hana Hana Hou (NGS): ʻO NGS kahi hana hoʻāʻo piha e hiki ke hoʻopaʻa ʻia i nā ʻano genes i ka manawa like. ʻAe kēia i ka ʻike ʻana i ka nui o nā mutation a me nā hoʻololi genomic ʻē aʻe.ʻO ka pane ʻana o nā kaulahao Polymerase (PCR): ʻO ka PCR kahi ʻano hoʻokolohua ʻoi aku ka nānā ʻana i hoʻohana ʻia no ka ʻike ʻana i nā mutation kikoʻī a i ʻole ka hoʻonohonoho hou ʻana o ke ʻano.ʻO Fluorescence In Situ Hybridization (FISH): Hoʻohana ʻia ka FISH e ʻike i nā hoʻonohonoho hou ʻana, e like me ka hui ʻana o ALK a me ROS1.Immunohistochemistry (IHC): Hoʻohana ʻia ʻo IHC no ka ʻike ʻana i ka ʻōlelo protein, e like me PD-L1, hiki ke kōkua i ka wānana i ka pane ʻana i ka immunotherapy. I ka manawa hea e hana ʻia ai ka hoʻāʻo ʻana Genetic? Pono e hana ʻia ka hoʻāʻo ʻana ma ke kaʻina hoʻolālā lapaʻau i hiki ke noʻonoʻo ʻia nā lāʻau lapaʻau mai ka hoʻomaka ʻana. He mea nui hoʻi e hoʻāʻo hou inā piʻi ka maʻi kanesa a i ʻole e loaʻa nā koho lapaʻau hou. genetic mutation ka mālama ʻana i ka maʻi kanesa. Hoʻolālā ʻia kēia mau lāʻau lapaʻau e hoʻopilikia i ka ulu ʻana, ka māhele ʻana, a me ka hoʻolaha ʻana o nā maʻi maʻi maʻi ʻoiai e hōʻemi ana i ka pōʻino i nā cell maʻamau. Hoʻohana ka lāʻau lapaʻau pilikino o ka Halemai Baofa i nā lāʻau lapaʻau kiʻekiʻe. Hoʻopili kēia mau lāʻau lapaʻau i ka hana o ka protein EGFR, ka mea i hana pinepine ʻia i loko o nā pūnaʻi kanesa me kēia mau hoʻololi. ʻO nā mea hoʻopaneʻe EGFR maʻamau ka:Gefitinib (Iressa)Erlotinib (Tarceva)Afatinib (Gilotrif)Osimertinib (Tagrisso): Hoʻohana pinepine ʻia ka lāʻau lapaʻau mua no ka EGFR-mutated NSCLC.ALK InhibitorsALK inhibitors no ka mālama ʻana i nā maʻi maʻi pūmāmā me nā hoʻonohonoho hou ʻana o ALK. Hoʻopaʻa kēia mau lāʻau lapaʻau i ka hana o ka protein ALK, ka mea maʻamau i ka hana maʻamau i loko o nā keʻena maʻi maʻi me kēia mau hoʻonohonoho hou. ʻO nā mea hoʻopaneʻe ALK maʻamau ka:Crizotinib (Xalkori)Alectinib (Alecensa)Ceritinib (Zykadia)Brigatinib (Alunbrig)Lorlatinib (Lobrena)Hoʻohana ʻia ka ROS1 InhibitorsROS1 no ka mālama ʻana i nā maʻi maʻi maʻi me ka hui pū ʻana o ROS1. Hoʻopaʻa kēia mau lāʻau lapaʻau i ka hana o ka protein ROS1, ka mea maʻamau i ka hana maʻamau i nā pūnaeho maʻi maʻi me kēia mau hui. ʻO nā mea hoʻopaneʻe ROS1 maʻamau ka:Crizotinib (Xalkori)Entrectinib (Rozlytrek)Hoʻohana ʻia ka BRAF Inhibitors BRAF inhibitors no ka mālama ʻana i nā maʻi maʻi ʻulaʻula me ka hoʻololi ʻana o BRAF, ʻoi aku ka hoʻololi ʻana o ka V600E. Hoʻopaʻa kēia mau lāʻau lapaʻau i ka hana o ka protein BRAF, ka mea pinepine i ka overactive i nā maʻi kanesa me kēia mau hoʻololi. ʻO nā mea pale BRAF maʻamau ka:Dabrafenib (Tafinlar)Trametinib (Mekinist): Hoʻohana pinepine ʻia i ka hui pū me dabrafenib.KRAS G12C InhibitorsSotorasib (Lumakras) a me Adagrasib (Krazati) he mau laʻana o KRAS G12C inhibitors i hoʻohana ʻia no ka mālama ʻana i nā maʻi maʻi maʻi me kēia hoʻololi KRAS kikoʻī. Hana lākou ma ke kāohi ʻana i ka hana o ka protein KRAS mutated.Immunotherapy and Genetic Mutations ʻO ka Immunotherapy kekahi ʻano o ka mālama ʻana i ka maʻi maʻi e kōkua i ke kino o ke kino e hakakā i ka maʻi kanesa. ʻOiai ʻaʻole pili pono ka immunotherapy genetic mutation ka mālama ʻana i ka maʻi kanesa, kekahi mau genetic mutations a me biomarkers, e like me ka PD-L1 expression a me ka tumor mutational burden (TMB), hiki ke wānana i ka pane ʻana i ka immunotherapy. ʻO nā maʻi me ka ʻōlelo PD-L1 kiʻekiʻe a i ʻole TMB kiʻekiʻe paha e pōmaikaʻi mai ka immunotherapy. Ma Shandong Baofa Cancer Research Institute, hoʻohui mākou i ka immunotherapy me nā ʻano lāʻau lapaʻau ʻē aʻe no ke ʻano holoʻokoʻa. ʻO ka Future of Lung Cancer TreatmentKe ulu wikiwiki nei ke kahua o ka mālama ʻana i ka maʻi kanesa. Ke kūkulu ʻia nei a hoʻāʻo ʻia nā lāʻau lapaʻau hou a me nā immunotherapies i nā hoʻokolohua lapaʻau. Ke hana nei nā mea noiʻi e ʻike i nā mea hou genetic mutation ka mālama ʻana i ka maʻi kanesa hiki ke kuhikuhi ʻia me nā lāʻau lapaʻau hou. Ke hoʻomaikaʻi nei ko mākou ʻike ʻana i ka genetics o ka maʻi maʻi maʻi, hiki iā mākou ke manaʻo e ʻike i nā koho lapaʻau pilikino a maikaʻi hoʻi no nā maʻi. Ua kūpaʻa ʻo Shandong Baofa Cancer Research Institute i ka noho ʻana ma ke poʻo o kēia mau holomua. Papa Hoʻohālikelike: ʻO nā mea lapaʻau i hoʻopaʻa ʻia e pili ana i nā MutationsMutationTargeted TherapiesDescriptionEGFROsimertinib, Gefitinib, Erlotinib, AfatinibBlock EGFR protein activityALKAlectinib, Crizotinib, Ceritinib, Lorlatiniblock activityBROS, Lorlatiniblock. EntrectinibBlock ROS1 protein activityBRAF V600EDabrafenib (pinepine me Trametinib) Block BRAF protein activityKRAS G12CSotorasib, AdagrasibBlock mutated KRAS protein activityConclusionHoʻomaopopo i ke kuleana o genetic mutation ka mālama ʻana i ka maʻi kanesa he mea nui ia no ka hoʻomaikaʻi ʻana i nā hopena no nā poʻe maʻi me ka maʻi kanesa maʻi. Hiki i ka hoʻāʻo ʻana ke kōkua i ka ʻike ʻana i nā mutation kikoʻī i hiki ke kuhikuhi ʻia me nā lāʻau lapaʻau pilikino. Ke hoʻomau nei ko mākou hoʻomaopopo ʻana i ka genetics o ka maʻi maʻi ʻaʻai māmā, hiki iā mākou ke manaʻo e ʻike i nā lāʻau lapaʻau ʻoi aku ka maikaʻi a hoʻopaʻa ʻia no kēia maʻi pōʻino. Kipa Shandong Baofa Cancer Research Institute e aʻo hou aʻe e pili ana i kā mākou ʻaoʻao piha i ka mālama ʻana i ka maʻi kanesa.Hōʻole: No ka hoʻonaʻauao wale nō kēia ʻike a ʻaʻole pono e manaʻo ʻia he ʻōlelo aʻoaʻo olakino. E kamaʻilio mau me kahi ʻoihana mālama ola kūpono no ka hōʻoia ʻana a me ka mālama ʻana i nā kūlana olakino.ReferencesNational Cancer Institute. www.cancer.govʻAmelika Hui Pū ʻIa. www.cancer.org